The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total global spending on medicines by 2016, and reach an overall market value of $200 billion to $210 billion in 2016, up from $157 billion in 2011. Seven of the top 10 global medicines by spending will be a biologic within the next 5 years.
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
PRA Insights Report 2017
The theme for this year’s DIA 2017 Annual Meeting was “Driving Insights to Action.” DIA hosted more than 7,000 professionals in the pharmaceutical,…
LC-MS/MS Support for Studies with Large Molecules
PRA’s Bioanalytical Laboratories provide LC-MS/MS services to support clients’ studies with biological and small molecules. The information details…